PhaseBio Pharmaceuticals Valuation
| PHASQDelisted Stock | USD 0.0003 0.0001 25.00% |
PhaseBio Pharmaceuticals seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of PhaseBio Pharmaceuticals from analyzing the company fundamentals such as Shares Owned By Institutions of 25.02 %, shares outstanding of 49.86 M, and Return On Asset of -1.06 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that PhaseBio Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of PhaseBio Pharmaceuticals is based on 3 months time horizon. Increasing PhaseBio Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
PhaseBio Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 0.0003, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.0E-4 | Real 2.85E-4 | Hype 3.75E-4 | Naive 0.001393 |
The intrinsic value of PhaseBio Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence PhaseBio Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of PhaseBio Pharmaceuticals helps investors to forecast how PhaseBio pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of PhaseBio Pharmaceuticals more accurately as focusing exclusively on PhaseBio Pharmaceuticals' fundamentals will not take into account other important factors: PhaseBio Pharmaceuticals Total Value Analysis
PhaseBio Pharmaceuticals is at this time projected to have takeover price of (1.26 M) with market capitalization of 1.05 M, debt of 1.36 M, and cash on hands of 7.8 M. The negative valuation of PhaseBio Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should thoroughly investigate all of the PhaseBio Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.26 M) | 1.05 M | 1.36 M | 7.8 M |
PhaseBio Pharmaceuticals Investor Information
About 25.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Based on the key indicators related to PhaseBio Pharmaceuticals' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, PhaseBio Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.PhaseBio Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. PhaseBio Pharmaceuticals has an asset utilization ratio of 17.89 percent. This connotes that the Company is making $0.18 for each dollar of assets. An increasing asset utilization means that PhaseBio Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.PhaseBio Pharmaceuticals Ownership Allocation
PhaseBio Pharmaceuticals owns a total of 49.86 Million outstanding shares. PhaseBio Pharmaceuticals holds 6.72 pct. of its outstanding shares held by insiders and 25.02 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.PhaseBio Pharmaceuticals Profitability Analysis
The company reported the revenue of 10.83 M. Net Loss for the year was (131.07 M) with loss before overhead, payroll, taxes, and interest of (91.28 M).About PhaseBio Pharmaceuticals Valuation
The pink sheet valuation mechanism determines PhaseBio Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of PhaseBio Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of PhaseBio Pharmaceuticals. We calculate exposure to PhaseBio Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of PhaseBio Pharmaceuticals's related companies.PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Phasebio Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 60 people.
8 Steps to conduct PhaseBio Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates PhaseBio Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct PhaseBio Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain PhaseBio Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine PhaseBio Pharmaceuticals' revenue streams: Identify PhaseBio Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research PhaseBio Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish PhaseBio Pharmaceuticals' growth potential: Evaluate PhaseBio Pharmaceuticals' management, business model, and growth potential.
- Determine PhaseBio Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate PhaseBio Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
PhaseBio Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as PhaseBio Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 48.2 M | |
| Retained Earnings | -391.8 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in PhaseBio Pink Sheet
If you are still planning to invest in PhaseBio Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseBio Pharmaceuticals' history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |